Enhancement in Specific CD8+ T cell Recognition of EphA2+ Tumors In Vitro and In Vivo After Treatment with Ligand Agonists()

The EphA2 receptor tyrosine kinase (RTK) is an attractive therapeutic target that is commonly overexpressed on solid tumors, with the degree of overexpression associated with disease progression, metastatic potential and poor prognosis. Agonistic monoclonal antibodies or ligand (ephrinA1)-Fc fusion...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wesa, Amy K., Herrem, Christopher J., Mandic, Maja, Taylor, Jennifer L., Vasquez, Cecilia, Kawabe, Mayumi, Tatsumi, Tomohide, Leibowitz, Michael S., Finke, James H., Bukowski, Ronald M., Bruckheimer, Elizabeth, Kinch, Michael S., Storkus, Walter J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2008
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3427921/
https://ncbi.nlm.nih.gov/pubmed/19017961
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak